ErbB-2/HER-2 protein expression, serum tumour necrosis factor-α (TFM-α) and soluble tumour necrosis factor receptor-2 (TNFR-2) concentrations in human carcinoma of the uterine cervix

European Journal of Gynaecological Oncology

Volumn 24, Issue 2, 2003, Pages 138-142

  Melczer, Z ^a   Banhidy F ^a   Csomor S ^a   Siklos P ^b   Dworak, O ^c   Cseh, K ^d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Dept of Gynaecological Oncology   (Germany)

^c Institute of Pathology   (Germany)

^d 1st Department of Internal Medicine and Cardiology   (Hungary)

Author keywords

Cervical cancer; ErbB 2; TNF ; TNFR 2

Indexed keywords

CONCANAVALIN A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOPOLYSACCHARIDE; ONCOPROTEIN; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; BLOOD; CANCER PATIENT; CANCER STAGING; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; ONCOGENE NEU; PROGNOSIS; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA;

ANTIGENS, CD; CERVIX UTERI; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA; UTERINE NEOPLASMS;

EID: 0037248711     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Hynes N. F., Stern D. F.: "The biology of erbB-2/neu/HER-2 and its role in cancer". Biochem. Biophys. Acta, 1994, 1198, 165.
2. Kolibaba K. S., Druker B. J.: "Protein tyrosine kinases and cancer". Biochem. Biophys. Acta, 1997, 1333, F217.
3. Thazar E., Yarden J.: "The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands". Biochem. Biophys. Acta, 1998, 1377, M25.
4. Brandt B., Vogt U., Schlotter C. M., Jackisch C., Werkmeister R., Thomas M. et al.: "Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis". Gene, 1995, 159 (1), 35.
5. Speer G., Dworak O., Cseh K., Bori Z., Salamon D., Török I. et al.: "Vitamin D receptor gene Bsml polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer". Oncology, 2000, 58, 242.
6. Bitran D., Samuels B., Trujillo Y., Klein L., Schroeder L., Martinec J.: "Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (> 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy". Clin. Cancer Res., 1996, 2 (9), 1509.
7. Aggarwal B. B., Natarajan K.: "Tumor necrosis factors: developments during the last decade". Eur. Cytokine Network, 1996, 7, 93.
8. Wallach D., Varfolomeev E. E., Malinin N. L., Goltsev Y. V., Kovalenko A. V., Boldin M. P.: "Tumor necrosis factor receptor and Fas signaling mechanisms". Ann. Rev. Immunol., 1999, 17, 331.
9. Maskos K., Fernandez-Catalan C., Huber R., Bourenkov G. P., Bartunik H., Ellestad G. A. et al.: "Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme", Proc. Natl. Acad. Sci. (USA), 1998, 95, 3408.
10. Galang C. K., Garcia-Ramirez J., Solski P. A., Westwick J. K., Der C. J., Neznanov N. N. et al.: "Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation". J. Biol. Chem., 1996, 271, 7992.
11. Cuello M., Ettenberg S. A., Clark A. S., Keane M. M., Posner R. H., Nau M. M. et al.: "Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-including ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2". Cancer Res., 2001, 61 (12), 4892.
12. Speer G., Cseh K., Winkler G., Takács I., Lakatos P.: "Estrogen and vitamin D receptor genotypes and the expression of erbB-2 and EGF receptor in human rectal cancer". Eur. J. Cancer, 2001, 37, 1463.
13. Cseh K., Jakab L., Török J., Kalabay L., Marticsek J., Pozsonyi T. et al.: "Fibronectin on the surface of lymphocytes". Immunol. Lett., 1985, 9, 301.
14. Cseh K., Beutler B.: "Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein". J. Biol. Chem., 1989, 264 (27), 16256.
15. Dankort D., Maslikowski B., Warner N., Kanno N., Kim H., Wang Z. et al.: "Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)- induced mammary tumorigenesis: implications for human breast cancer". Mol. Cell. Biol., 2001, 21 (5), 1540.
16. Katsaros D., Theillet C., Zola P., Louason G., Sanfilippo B., Isaia E. et al.: "Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients". Anticancer Res., 1995, 15 (4), 1501.
17. Bankfalvi A., Simon R., Brandt B., Burger H., Vollmer I., Dockhorn-Dworniczak B. et al.: "Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use". Histopathology, 2000, 37 (5), 411.
18. Cardillo M., Yankelevich B., Mazumder A., Lupu R.: "Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells". Cancer Immunol. Immunother., 1996, 43 (1), 19.